35 results about "Cannabidivarin" patented technology

This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.

The invention discloses a composition for preventing and / or treating female dysmenorrhea. The composition is prepared from cannabidiol and / or cannabidivarin, a penetration enhancer and a carrier, wherein the mass ratio of the cannabidiol and / or cannabidivarin to the penetration enhancer is 1:(0.1-0.8). The composition has the advantages that the female dysmenorrheal can be effectively relieved, and the problem that in the prior art, a cannabidiol and / or cannabidivarin composition capable of effectively preventing and / or treating the female dysmenorrhea is in shortage can be solved; and meanwhile, the composition can also be used for preparing female hygienic aids for preventing and / or treating the female dysmenorrhea.

The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.

The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and / or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.

The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and / or purified from cannabis plant extracts.

The invention relates to a preparation method of a cannabidivarin crystal. The method comprises the steps of: (1) extracting industrial cannabis sativa powder with a first solvent, and concentrating a leaching solution containing cannabidivarin obtained after extraction to obtain a concentrated extract; (2) dissolving the concentrated extract in an alkaline aqueous solution, and carrying out saponifying; (3) adding a second solvent into the mixture in the step (2) for first extraction, adding a third solvent into the lower-layer water phase for second extraction, and concentrating an upper-layer extract obtained from the second extraction to obtain a refined substance; (4) dissolving the refined substance in a fourth solvent, performing chromatographic purification, and concentrating the eluent to obtain a cannabidivarin oily substance; and (5) mixing the oily substance with a crystallization solvent, and crystallizing. According to the method, a high-purity cannabidivarin crystal can be obtained at a high total extraction rate, the energy consumption is low, the consumption of the organic solvent is low, the method is more energy-saving and environment-friendly, the method is particularly suitable for industrial application, and the crystal product does not contain addictive components.

The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.

The invention discloses a method for preparing secondary cannabidiol, which at least comprises the following steps: a) pretreating a raw material containing industrial hemp to obtain a pretreated material; b) performing alcohol extraction on the pretreated material, concentrating an extracting solution I to obtain a concentrated solution, adding water for decarboxylation, and concentrating II to obtain a dry extract; c) mixing the dry extract and an adsorbent I to form a solid dispersion system, and performing solid-phase extraction to obtain a secondary cannabidiol primary product solution; d) subjecting the crude cannabidiol solution to concentration III, decoloration and crystallization so as to obtain the secondary cannabidiol. The preparation method is simple in process, high in product transfer rate, time-saving, labor-saving, large in treatment capacity, high in product purity and suitable for industrial large-scale production.

Methods of manufacturing cannabidiol (CBD) and cannabidivarin (CBDV); intermediates of the methods of manufacturing CBD and CBDV; and crystallized CBD and CBDV obtained via described methods.

The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w / w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.

The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and / or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.

The invention discloses an ASBDV composition for improving sleep disorders, and a preparation and an application thereof. The ASBDV composition for improving sleep disorders is composed of astaxanthin and cannabidiol. The preparation of the ASBDV composition for improving sleep disorders is a tablet, an oral liquid, a capsule, a granule, a powder, a pill, an injection, a film or a patch prepared by adding auxiliary materials to the ASBDV composition. The application is an application of the ASBDV composition for improving sleep disorders in the preparation of products for preventing / improving sleep disorders. The astaxanthin and cannabidivarol composition (ASBDV) has an obvious improvement effect on sleep disorders.

The invention discloses a composition for preventing and / or treating gynecologic inflammation. The composition comprises cannabidiol, cannabidivarin and a carrier, wherein the mass ratio of the cannabidiol to the cannabidivarin is (0.2 to 10):1. The defect of shortage of a composition containing cannabidiol substances for effectively preventing and / or treating gynecologic inflammation in the priorart is overcome. Meanwhile, the composition provided by the invention can also be used for preparing a female sanitation article for preventing and / or treating gynecologic inflammation.